Grifols SA, Barcelona (NASDAQ:GRFS) was upgraded by investment analysts at HSBC from a “reduce” rating to a “hold” rating in a research note issued on Wednesday.
Other research analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. UBS Group cut shares of Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. ValuEngine upgraded shares of Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, Morgan Stanley reduced their price target on shares of Grifols SA, Barcelona from $23.00 to $22.00 and set an “underweight” rating on the stock in a research report on Thursday, March 1st. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $23.00.
Grifols SA, Barcelona (NASDAQ:GRFS) opened at $21.72 on Wednesday. The company has a debt-to-equity ratio of 1.62, a current ratio of 3.01 and a quick ratio of 1.35. The firm has a market cap of $14,653.38, a P/E ratio of 19.87, a P/E/G ratio of 1.36 and a beta of 1.18. Grifols SA, Barcelona has a 52-week low of $17.28 and a 52-week high of $25.18.
Hedge funds and other institutional investors have recently modified their holdings of the business. Lenox Wealth Management Inc. grew its position in Grifols SA, Barcelona by 8,372.9% during the third quarter. Lenox Wealth Management Inc. now owns 5,931 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 5,861 shares during the last quarter. First Republic Investment Management Inc. purchased a new stake in shares of Grifols SA, Barcelona during the third quarter valued at approximately $203,000. Dean Capital Investments Management LLC purchased a new stake in shares of Grifols SA, Barcelona during the fourth quarter valued at approximately $214,000. Pitcairn Co. purchased a new stake in shares of Grifols SA, Barcelona during the fourth quarter valued at approximately $228,000. Finally, Dowling & Yahnke LLC purchased a new stake in shares of Grifols SA, Barcelona during the fourth quarter valued at approximately $327,000. Institutional investors and hedge funds own 22.26% of the company’s stock.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/16/hsbc-upgrades-grifols-sa-barcelona-grfs-to-hold.html.
Grifols SA, Barcelona Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.